PMHNP Scope of Practice for General Psychiatry in New York

If you’re a psychiatrist or psychiatric NP considering telehealth—or already practicing remotely—you’ve probably asked yourself: ‘Can I legally prescribe Adderall, Xanax, or buprenorphine to patients I’ve never met in person?’

The short answer in 2026: Yes, but it’s complicated. And the rules are about to change again.

Federal telehealth flexibilities that started during COVID have been extended through the end of 2026, allowing you to prescribe Schedule II–V controlled substances via video visits without an initial in-person exam. But the DEA is finalizing permanent rules that will likely require new registrations, impose time limits on certain prescriptions, and add oversight requirements for telehealth platforms.

Meanwhile, state laws vary wildly. Florida explicitly allows Schedule II prescribing via telehealth for psychiatric treatment. Texas prohibits NPs from prescribing Schedule II stimulants in outpatient settings at all. California mandates checking the PDMP every four months. Pennsylvania has no telehealth statute but expects standard-of-care compliance.

This guide breaks down:

• Current federal DEA rules and what’s changing in 2026
• State-by-state telehealth prescribing requirements for psychiatrists and PMHNPs
• Scope-of-practice differences (MD vs NP authority)
• PDMP, e-prescribing, and compliance essentials
• What the proposed DEA rules mean for your practice

Let’s cut through the confusion.

The Current Federal Landscape: DEA Extensions Through 2026

Where We Stand Today

As of February 2026, psychiatrists and psychiatric NPs can prescribe controlled substances via telehealth without an in-person visit, thanks to temporary DEA flexibilities extended through December 31, 2026. This is the fourth extension of COVID-era waivers that suspended the Ryan Haight Act’s in-person exam requirement.

What this means practically:

• You can initiate treatment with Schedule II stimulants (Adderall, Ritalin) for ADHD via video consultation
• You can prescribe benzodiazepines, Z-drugs, and other controlled medications to new patients you’ve never seen in person
• The patient-provider relationship can be established through real-time audio-visual telehealth

Key requirement: You must use interactive, two-way video for initial evaluations. Audio-only telephone doesn’t meet the standard for most controlled substances (except buprenorphine for opioid use disorder—more on that below).

The Ryan Haight Act Context

The Ryan Haight Act of 2008 originally required at least one in-person medical evaluation before prescribing controlled substances via the internet. It was passed to combat rogue online pharmacies selling painkillers with no medical oversight.

The law carved out exceptions—like patients being evaluated at a DEA-registered facility or prescribers obtaining a special ‘telemedicine registration’—but that registration process was never actually implemented before COVID.

Important distinction: If a patient was ever seen in person by you or another provider in your practice, the Ryan Haight Act’s requirement is already satisfied. You can prescribe controlled medications via telehealth indefinitely to that patient. The restrictions only apply to patients you’ve never examined in person.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: Proposed DEA Rules for 2026 and Beyond

The DEA has proposed three new rules to replace temporary waivers. They’re still accepting public comments, but here’s what psychiatrists need to know:

1. Special Telemedicine Registration for Schedule II Prescribing

The proposal: The DEA would create a new Special Telemedicine Prescriber Registration that allows qualified providers to prescribe controlled substances to new patients without an in-person exam.

Who qualifies for Schedule II authority:

• Board-certified psychiatrists
• Hospice and palliative care physicians
• Long-term care facility physicians
• Pediatricians (for specific narrow uses)

For Schedule III–V substances, any qualified prescriber could obtain this registration.

Why this matters: If finalized, board-certified psychiatrists could register to prescribe Schedule II stimulants (Adderall, Vyvanse, etc.) via telehealth indefinitely without the patient ever having an in-person visit. This would legitimize and expand telepsychiatry’s role in ADHD management.

The catch: Telehealth platforms themselves would need to register with the DEA and comply with new oversight requirements, including integration with a national PDMP system. Expect more administrative steps and reporting.

2. Buprenorphine Expansion for Opioid Use Disorder

The DEA proposes allowing six months of buprenorphine treatment via telehealth (including audio-only) before an in-person visit is required. After 180 days, providers must conduct or arrange an in-person evaluation for ongoing treatment.

This is more permissive than current law and acknowledges how telehealth has improved access to addiction treatment. Combined with the 2023 elimination of the X-waiver (any DEA-registered provider can now prescribe buprenorphine), this could significantly expand MAT access.

Relevance for psychiatrists: If you treat opioid use disorder or co-occurring psychiatric conditions, this rule gives you a clear six-month runway to stabilize patients before requiring an in-person touchpoint.

3. National PDMP and Platform Registration

The proposed rules would establish a national Prescription Drug Monitoring Program integrating state PDMP data for easier cross-state monitoring. Telehealth companies would be required to register and could face sanctions if they facilitate inappropriate prescribing.

This is the DEA’s response to high-profile cases of telehealth startups allegedly over-prescribing stimulants with inadequate evaluations.

Timeline: These rules could be finalized sometime in 2026. Until then, the temporary extension remains in effect through December 31, 2026.

State-by-State Rules: Where Telehealth Prescribing Gets Complicated

Federal law sets the floor, but states can (and do) impose stricter rules. Here’s what you need to know in key markets:

California: Telehealth-Friendly with PDMP Requirements

Controlled substance prescribing: No state restriction beyond federal law. Video visits establish a valid patient relationship.

PMHNP independence: California is transitioning to full practice authority for experienced NPs. As of 2023, NPs with ≥3 years supervised practice can work independently in group settings. By 2026, they’ll be able to open independent practices with no physician oversight.

Compliance essentials:

• Mandatory CURES PDMP check before first prescribing Schedule II–IV and every four months for ongoing treatment
• 100% e-prescribing required (since January 2022)
• Audio-only telehealth is allowed for follow-ups but video is strongly recommended for initial controlled substance evaluations

Bottom line: California embraces telehealth but demands rigorous PDMP monitoring. If you’re managing a patient on ongoing stimulants or benzodiazepines, set calendar reminders to check CURES every 120 days.

Texas: Physician-Only Schedule II, Tight NP Restrictions

Controlled substance prescribing: Allowed via telehealth under federal waiver. Real-time audio-video required to establish care.

Major restriction: Texas prohibits NPs and PAs from prescribing Schedule II outside hospital or hospice settings. This means:

• Any outpatient patient needing Adderall, Vyvanse, or other Schedule II stimulants must see a physician
• PMHNPs can prescribe Schedule III–V (many anxiety meds, sleep aids) under physician delegation

Chronic pain prohibition: Texas law bans telehealth prescribing of controlled substances for chronic pain management without an in-person exam. (This rarely affects psychiatry but is relevant if treating somatic symptom disorders.)

Compliance essentials:

• Mandatory Texas PMP check before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol
• NPs must have written physician delegation agreements for all practice
• E-prescribing expected (state mandate coming)

Bottom line: Texas telepsychiatry requires MDs for stimulant management. Platforms operating in Texas typically pair NPs with supervising psychiatrists specifically for Schedule II prescriptions.

Florida: Psychiatric Exception Saves the Day

Controlled substance prescribing: Florida has a strict ban on Schedule II prescribing via telehealth—except for psychiatric treatment, inpatient care, hospice, or nursing home residents.

This psychiatric exception means you can prescribe Adderall for ADHD via telehealth in Florida, but the indication must be documented as psychiatric treatment.

Out-of-state provider option: Florida allows out-of-state providers to register as telehealth providers without obtaining a full Florida license. However, you’re still bound by Florida’s controlled substance prescribing rules.

PMHNP restrictions: Psychiatric NPs in Florida require a collaborative agreement with a supervising physician (no independent practice for psych specialty).

Compliance essentials:

• Mandatory E-FORCSE PDMP check before prescribing any controlled substance to patients ≥16
• Must designate yourself as a controlled substance prescriber on your Florida DOH profile if prescribing for chronic pain (rare in psychiatry)
• E-prescribing required since 2021

Bottom line: Florida welcomes telepsychiatry for mental health but watch the fine print. Document psychiatric indications clearly and use the out-of-state registration if you’re not Florida-licensed.

New York: PDMP-Heavy, NP-Friendly

Controlled substance prescribing: No state restriction beyond federal law. Video establishes care.

PMHNP independence: NPs with >3,600 clinical hours can practice fully independently (no collaborative agreement required). New NPs need physician oversight until they hit that threshold.

Compliance essentials:

• Mandatory I-STOP PMP check before prescribing every Schedule II, III, or IV controlled substance (strictest PDMP mandate in the nation)
• 100% e-prescribing required since 2016 (New York was first state to mandate this for all prescriptions)
• Audio-only mental health telehealth is reimbursable, but video is best practice for controlled substance evaluations

Bottom line: New York is highly telehealth-friendly and supports NP independence, but the PDMP requirement is non-negotiable. Every controlled substance prescription = PMP query. Build it into your workflow.

Pennsylvania: No Telehealth Law, Standard-of-Care Governs

Controlled substance prescribing: Allowed via telehealth under standard-of-care principles. No state law explicitly addressing it (multiple bills have stalled).

PMHNP restrictions: NPs require collaborative agreements with at least two physicians for prescriptive authority. Schedule II limited to 30-day supply; Schedule III–IV to 90 days.

Compliance essentials:

• Mandatory PA PMP check before prescribing opioids or benzodiazepines (and recommended for all controlled substances)
• E-prescribing required for controlled substances since 2019
• Document patient consent for telehealth (no statutory requirement but best practice)

Bottom line: Pennsylvania operates in a regulatory gray zone for telehealth, relying on professional judgment. Follow standard-of-care principles, document thoroughly, and ensure NP collaboration agreements are current.

Illinois: Full Practice Available, Some Controlled Substance Limits

Controlled substance prescribing: No state ban on telehealth prescribing. Follow federal law and standard of care.

PMHNP independence: NPs can obtain Full Practice Authority (FPA) license after 4,000 hours and 250 hours of additional training. However, even FPA NPs must have a physician ‘consultation relationship’ to prescribe benzodiazepines or Schedule II opioids, limited to 30-day supplies.

Compliance essentials:

• Mandatory IL PMP check before each opioid prescription (and recommended for all controlled substances)
• E-prescribing required for all controlled substances since January 2023
• Document physician consultation if prescribing benzos or Schedule II under FPA

Bottom line: Illinois supports NP independence with some strings attached. The consultation requirement for benzos and Schedule II is a compromise but still allows broad telehealth prescribing.

Psychiatrist vs PMHNP Scope of Practice: What You Need to Know

Psychiatrists (MD/DO): Full Authority, Everywhere

Psychiatrists have unrestricted independent practice authority in all 50 states. You can:

• Diagnose all psychiatric conditions
• Prescribe all controlled substances (Schedule II–V) as medically appropriate
• Practice telehealth in any state where you hold a medical license

No supervision required. No collaborative agreements. No Schedule II restrictions.

The only regulatory limits you face are:

• Must be licensed in the state where the patient is located
• Must follow that state’s telehealth prescribing rules
• Must comply with DEA and state PDMP/e-prescribing mandates

PMHNPs: Authority Varies Wildly by State

Psychiatric Mental Health Nurse Practitioners face a patchwork of state laws governing their scope of practice:

Full Practice States (after meeting requirements):

• New York: 3,600 hours → full independence
• California: 3 years supervised → independent practice by 2026
• Illinois: 4,000 hours + 250 hours training → FPA (with consultation requirement for benzos/Schedule II)

Reduced Practice States:

• Pennsylvania: Always requires collaborative agreement with ≥2 physicians; Schedule II limited to 30-day supply

Restricted Practice States:

• Texas: Always requires physician supervision; cannot prescribe Schedule II in outpatient settings
• Florida: Always requires collaborative agreement for psych NPs (no independent practice even though some primary care NPs can)

What This Means for Telehealth Platforms

If you’re joining a platform or building a multi-state practice:

• In Texas and Florida, you’ll need a supervising physician relationship documented
• In New York and California (post-2026), experienced NPs can practice fully independently
• In Pennsylvania and Illinois, you’ll need formal collaboration agreements even if you have significant autonomy

Key takeaway: Always check the state nursing board rules where your patients are located. ‘PMHNP’ authority in one state tells you nothing about what you can do in another.

The Economics of Telehealth: Why Platforms Beat DIY Marketing

Here’s the reality most providers don’t talk about: acquiring psychiatric patients through traditional marketing is expensive and slow.

The True Cost of DIY Patient Acquisition

Let’s break down what it actually costs to build a patient base from scratch:

SEO (Search Engine Optimization):

• Takes 6–12 months of consistent investment before meaningful results
• Requires ongoing content creation, technical optimization, and link building
• Cost: $1,500–$3,000/month for a decent agency, plus your time
• Risk: Algorithm changes can tank your rankings overnight

Google Ads:

• Mental health keywords cost $15–$40+ per click
• Most clicks don’t convert to booked patients
• Realistic cost per booked patient: $200–$400+ after accounting for testing, optimization, and no-shows
• Requires expertise to avoid burning money on bad campaigns

Directory Listings (Psychology Today, Zocdoc):

• Monthly subscription fees ($30–$100+)
• Compete with hundreds of other providers on the same page
• Zocdoc charges $35–$100+ per booking on top of subscription
• Total monthly cost adds up fast with multiple directories

Reality check: Most solo providers spend $3,000–$5,000/month on marketing with uncertain results for the first 6–12 months. That’s $36,000–$60,000 before you have a reliable patient flow.

The Platform Model: Pay Only for Patients You See

Telehealth platforms like Klarity Health use a fundamentally different model:

• No upfront marketing spend or monthly subscriptions
• Pay a standard listing fee per new patient lead (similar to Zocdoc’s per-booking model)
• Patients are pre-qualified and matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Access to both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

The economic advantage: Instead of gambling $3,000–$5,000/month on marketing channels with uncertain ROI, you pay only when a qualified patient books with you. That’s guaranteed ROI vs. speculative marketing spend.

When DIY makes sense: If you have deep pockets, marketing expertise, and patience to wait 6–12 months for SEO and paid ads to mature, DIY can eventually be cost-effective. But for most providers—especially those starting out or scaling quickly—a platform removes the risk entirely.

Compliance Essentials: PDMP, E-Prescribing, and Documentation

PDMP (Prescription Drug Monitoring Program) Requirements

Nearly every state now mandates PDMP checks before prescribing controlled substances:

Strictest states:

• New York: Check before every Schedule II–IV prescription
• California: Check before first prescription and every 4 months
• Texas: Mandatory for opioids, benzos, barbiturates, and carisoprodol

Best practice: Check the PDMP for every new patient receiving controlled substances and periodically for ongoing treatment, even if your state doesn’t explicitly require it. It protects you medically and legally.

Most states now participate in Interstate PDMP data sharing (PMP Interconnect), so you can see controlled substance fills from neighboring states.

E-Prescribing Mandates

States requiring e-prescribing for controlled substances:

• California (all prescriptions, 2022)
• New York (all prescriptions, 2016)
• Illinois (controlled substances, 2023)
• Florida (controlled substances, 2021)
• Pennsylvania (controlled substances, 2019)
• Texas (pending, but expected)

Federal requirement: Medicare Part D requires e-prescribing for controlled substances (since 2021) with limited exceptions.

Telehealth platforms handle this automatically, but if you’re setting up your own practice, ensure your e-prescribing system is DEA-compliant (two-factor authentication required).

Documentation Standards

For telehealth encounters involving controlled substances, document:

• Chief complaint and psychiatric history
• Mental status examination findings (even via video, you can assess appearance, affect, thought process, etc.)
• Rationale for controlled substance (diagnosis, failed alternatives, risk-benefit discussion)
• Patient consent for telehealth treatment
• PDMP query results
• Plan for follow-up and monitoring

Pro tip: Document more thoroughly for Schedule II prescriptions. If you’re ever audited, detailed notes demonstrating a legitimate patient-provider relationship and medical necessity are your best defense.

DEA Training Requirements (MATE Act)

Since June 2023, all DEA registrants must complete a one-time 8-hour training on substance use disorders and appropriate prescribing before their next DEA renewal.

Who’s covered:

• Physicians (including psychiatrists)
• NPs and PAs with prescriptive authority
• Dentists, optometrists, and other prescribers

Who’s exempt:

• Board-certified addiction psychiatrists or addiction medicine specialists (certification counts as training)
• Providers who completed equivalent training in medical school or residency (but you must attest to this)

What the training covers:

• Recognizing substance use disorders
• Appropriate opioid and controlled substance prescribing
• Non-pharmacologic pain management alternatives

Where to get it: SAMHSA maintains a list of approved training providers. Many medical boards and specialty organizations offer free or low-cost courses.

FAQs: What Providers Actually Want to Know

Q: Can I prescribe Adderall via telehealth to a new patient I’ve never met in person?

A: Yes, through December 31, 2026, under the federal DEA extension. You must conduct a thorough evaluation via real-time video and document it appropriately. After 2026, you’ll likely need the new DEA Special Telemedicine Registration (if you’re a board-certified psychiatrist) or must have seen the patient in person.

Q: Do I need a separate medical license in every state where my patients are located?

A: Yes. Telehealth is considered to occur where the patient is physically located. You must be licensed (or registered, in states like Florida that allow it) in that state. Interstate compacts (IMLC for MDs, some nursing compacts for RNs) can streamline this but don’t eliminate the requirement.

Q: Can I prescribe controlled substances using audio-only telephone visits?

A: Generally no, except for buprenorphine for opioid use disorder where audio-only is explicitly allowed (and may be extended for six months under proposed rules). For other controlled substances, best practice is interactive audio-video. Some states permit audio-only for follow-up visits in established patients, but initial controlled substance evaluations should be via video.

Q: What happens if the DEA extension expires before permanent rules are finalized?

A: If the extension isn’t renewed by December 31, 2026, the Ryan Haight Act’s in-person exam requirement would technically revert. However, given the political and clinical pressure to maintain telehealth access, another extension or emergency finalization of the new rules is likely. The DEA has explicitly stated they’re extending to avoid care disruptions ‘while permanent rules are finalized.’

Q: As a PMHNP, can I prescribe stimulants via telehealth independently?

A: It depends entirely on your state:

• New York (with >3,600 hours): Yes, fully independently
• California (by 2026 with experience): Yes, independently
• Texas: No—you cannot prescribe Schedule II in outpatient settings at all; a supervising physician must write those prescriptions
• Florida: No—you need a collaborative agreement, and the supervising physician must oversee
• Illinois (with FPA): Yes, but with consultation requirement for benzos and Schedule II, limited to 30-day supplies

Q: Do I need malpractice insurance that covers telehealth?

A: Yes. Many malpractice policies now include telehealth automatically, but verify your coverage extends to all states where you practice and specifically covers controlled substance prescribing via telemedicine.

What This Means for Your Practice in 2026

If You’re a Psychiatrist:

You have the most flexibility. Current federal rules allow you to prescribe any psychiatric medication via telehealth through 2026. The proposed DEA rules would formalize and expand this through a Special Telemedicine Registration for board-certified psychiatrists.

Action items:

• Ensure you’re licensed in all states where you see patients
• Check state PDMP requirements and build them into your workflow
• Consider obtaining licenses in high-demand states (Texas, Florida, California) if you want to expand
• Watch for DEA’s final rules—you may need to register and pay a fee for the special telemedicine authority

If You’re a PMHNP:

Your authority varies dramatically by state. In full-practice states, you have nearly the same flexibility as psychiatrists. In restricted states, you’ll need physician collaboration.

Action items:

• Verify your state’s PMHNP scope of practice laws
• If working in a restricted state (Texas, Florida), ensure you have a written collaborative agreement
• If you have the hours, apply for full practice authority in states that offer it (New York, California, Illinois)
• Clarify with telehealth platforms what supervision or collaboration they provide

If You’re Building a Multi-State Telehealth Practice:

Reality check: Compliance complexity increases exponentially with each state you add. Each new state means:

• Another medical/nursing license ($300–$1,000+ application, ongoing renewal fees)
• Another DEA registration ($731 for 3 years)
• Learning that state’s PDMP, e-prescribing, and telehealth rules
• Potentially another malpractice policy endorsement

The platform advantage: Telehealth companies like Klarity Health handle much of this infrastructure—credentialing, compliance monitoring, patient matching across states. You focus on clinical care; they handle the regulatory maze.

Looking Ahead: What to Watch in 2026

Q1 2026: DEA comment period closes on proposed telemedicine rules. Watch for final rules published in Federal Register.

Mid-2026: Likely effective date for new DEA Special Telemedicine Registration. Expect application process, fees, and compliance requirements to be announced.

Late 2026: Current DEA extension expires December 31, 2026. Either permanent rules take effect or another extension is issued.

California 2026: First cohort of PMHNPs with full independent practice authority (Category 104) expected to complete requirements, allowing solo practice with no physician oversight.

State legislatures: Several states are considering telehealth bills (Pennsylvania comprehensive telehealth law, Texas potential NP scope expansion, others). These could significantly change state landscapes.

The Bottom Line

Prescribing controlled substances via telehealth is legal in 2026 under federal extensions, and likely to remain so under proposed DEA rules—with some new administrative requirements. But state laws create a maze of additional restrictions, PDMP mandates, and scope-of-practice limitations that vary wildly.

For psychiatrists: You have maximum flexibility. Stay licensed where you practice, follow state rules, and prepare for the new DEA registration process.

For PMHNPs: Your authority depends entirely on where you practice. Full practice states give you near-physician autonomy; restricted states require collaboration and may limit Schedule II prescribing.

For all providers: The economics of building a telehealth practice from scratch are daunting—$3,000–$5,000/month in marketing spend for 6–12 months before seeing ROI. Platforms that handle patient acquisition and pay-per-appointment models eliminate that upfront risk.

The future of telepsychiatry is bright, but navigating the regulatory landscape requires diligence. Stay informed, document thoroughly, and don’t hesitate to seek legal or compliance counsel when needed.

Ready to Practice Telepsychiatry Without the Marketing Headache?

Klarity Health connects board-certified psychiatrists and psychiatric NPs with pre-qualified patients across multiple states—handling licensing support, credentialing, and patient acquisition so you can focus on clinical care.

No upfront costs. No monthly subscriptions. Pay only when you see patients.

Explore provider opportunities with Klarity Health →

Sources & Citations

1. U.S. Department of Health and Human Services (HHS) – Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026,’ January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration (DEA) – Press Release: ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Vital Medicines,’ January 16, 2025. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Florida Statutes §456.47 – Use of telehealth to provide services (2025 edition). Florida Legislature Online Sunshine. http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

4. Akerman LLP – ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth,’ March 2023. https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

5. Texas Medical Board – Prescriptive Authority FAQs (Updated 2024). https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. Telehealth regulations are rapidly evolving. Always consult your state medical or nursing board, DEA regional office, and legal counsel for guidance specific to your practice. The information herein reflects laws and proposed rules as of February 2026 and is subject to change.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices